ACLY and systemic lupus erythematosus: Previous studies have also shown a result almost similar to ours, showing rates of adverse clinical outcomes to be higher in APS and SLE patients, and these studies have linked levels of aCL antibodies with the increased risk of MI and cardiac deaths.20 Researches have shown a strong association between the levels of aCL antibodies and the adverse cardiovascular outcomes after PCI.